Vertex Pharmaceuticals Inc. (VRTX) announced positive results from a viral kinetic study of the nucleotide analogue ALS-2200 after the bell Monday, for the treatment of hepatitis C. There was a median 4.54 log10 reduction in hepatitis C virus RNA in people with genotype 1 chronic hepatitis C who were new to treatment after seven days of dosing with 200 mg of ALS-2200 once daily.
The company also reported second quarter non-GAAP net income of $0.46 per share, which fell short of the consensus estimate of $0.59.
Vertex Pharmaceuticals was range-bound for the majority of Monday's session and closed up by 0.64 at $49.96. The stock finished near the upper end of a one-week range. Vertex is now up 3.79 on 113K shares after the bell.
For comments and feedback: editorial@rttnews.com